icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: real-world data from Georgian hepatitis C elimination program
 
 
    Reported by Jules Levin
AASLD Liver Meeting Oct 20-24 2017, Washington DC 
Tengiz Tsertsvadze,1,2 Nikoloz Chkhartishvili,1 Akaki Abutidze,1 Lali Sharvadze,2,3 Vakhtang Kerashvili,1 Maia Butsashvili,4 Jaba Zarkua,5 Lia Gvinjilia,6 Muazzam Nasrullah,7 Amiran Gamkrelidze,8 Valeri Kvaratskhelia,9 Nezam Afdhal,10 Sanjeev Arora,11 Stefan Zeuzem,12 Karla Thornton,11 Francisco Averhoff 7 
Infectious Diseases, AIDS and Clinical Immunology Research Center 1Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia 2Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia 3Hepatology Clinic Hepa, Tbilisi, Georgia 4NeoLab, Tbilisi, Georgia 5 Medical Center Mrcheveli, Tbilisi, Georgia 6CDC Foundation, Tbilisi, Georgia 7Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, GA, USA 8National Center for Disease Control and Public Health, Tbilisi, Georgia 9Ministry of Labour, Health and Social Affairs of Georgia, Tbilisi, Georgia 10 Harvard Medical School, Boston, MA, USA 11 University of New Mexico, Albuquerque, NM, USA 12Goethe University Hospital, Frankfurt, Germany

1106171

1106172